Results: A novel xenograft cohort comprising 10 individual HG-SOC (out of 15 HG-SOC transplanted; two failed by 300d; 3 under observation; xenograft success rate 77%) has been generated, including proven successful cryopreservation ensuring xenograft supply. BROCA analysis3 of tumour samples has revealed 3 HG-SOC with BRCA2 mutations and 2 with BRCA1 mutations (the germline status of these mutations is being determined) and for five other HG-SOC, no DNA repair gene mutations were found (apart from in the p53 pathway, which is presumed mutated in all). In vivo platinum response data is available for 7 individual HG-SOC, three were platinum sensitive (Progressive Disease (PD)≥100 d post platinum), two were platinum resistant (PD<100 d) and two were platinum refractory (PD on platinum). Relapsed tumours are retreated in vivo or harvested for molecular analysis and serial transplantation followed by re-treatment.
Conclusions: We will report correlation of molecular characteristics with drug response outcome. The invaluable “paired” samples (pre and post drug treatment) will allow clonal evolution analysis of mechanisms of drug response and resistance.